Poly-ε-caprolactone intravitreous devices: An in vivo study

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 5, 2009, Pages 2312-2318

  Silva Cunha, Armando ^a,b   Fialho, Silvia Ligorio ^b,c   Naud, Marie Christine ^b   Behar Cohen, Francine ^b,d,e  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c FUNDAÇÃO EZEQUIEL DIAS   (Brazil)

^d HÔTEL DIEU   (France)

^e FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; POLYCAPROLACTONE; BIOMATERIAL; DRUG CARRIER; POLYESTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIODEGRADATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TOLERABILITY; EYE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RABBIT; SCANNING ELECTRON MICROSCOPY; TREATMENT DURATION; ANIMAL; ANTERIOR EYE SEGMENT; BIOAVAILABILITY; BIODEGRADABLE IMPLANT; DRUG EFFECT; DRUG IMPLANT; FEASIBILITY STUDY; HALF LIFE TIME; INTRAOCULAR PRESSURE; METABOLISM; PATHOLOGY; VITREOUS BODY;

ABSORBABLE IMPLANTS; ANIMALS; ANTERIOR EYE SEGMENT; BIOCOMPATIBLE MATERIALS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEXAMETHASONE; DRUG CARRIERS; DRUG IMPLANTS; FEASIBILITY STUDIES; HALF-LIFE; INTRAOCULAR PRESSURE; MICROSCOPY, ELECTRON, SCANNING; POLYESTERS; RABBITS; VITREOUS BODY;

EID: 65549148169     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2969     Document Type: Article

References (39)

1. Kimura H, Ogura Y. Biodegradable polymers for ocular drug delivery. Ophthalmologica. 2001;215:143-155.
2. Fialho SL, Behar-Cohen F, Silva Cunha A. Dexamethasone-loaded poly- -caprolactone intravitreal implants: a pilot study. Eur J Pharm Biopharm. 2008;68:637-646.
3. The United States Pharmacopeia 29 ed. (USP 29) Rockville: United States Pharmacopeial Convention Inc. CD-ROM. Insight Publishing Productivity; 2006.
4. Einmahl S, Behar-Cohen F, D'Hermies F, et al. A new poly(orthoester)-based drug delivery system as an adjunct treatment in filter-ing surgery. Invest Ophthalmol Vis Sci. 2001;42:695-700.
5. Behar-Cohen F, Parel JM, Pouliquen Y, et al. Iontophoresis of dexamethasone in the treatment of endotoxin-induced-uveitis in rats. Exp Eye Res. 1997;65:533-545.
6. Peyman GA, Ganiban GJ. Delivery systems for intraocular routes. Adv Drug Del Rev. 1995;16:107-123.
7. Yasukawa T, Ogura Y, Tabata Y, Kimura H, Wiedemann P, Honda Y. Drug delivery systems for vitreoretinal diseases. Prog Retin Eye Res. 2004;23:253-281.
8. Hashizoe M, Ogura Y, Kimura H, et al. Scleral plug of biodegradable polymers for controlled drug release in the vitreous. Arch Ophthalmol. 1994;112:1380-1384.
9. Kimura H, Ogura Y, Hashizoe M, Nishiwaki H, Honda Y, Ikada Y. A new vitreal drug delivery system using an implantable biode-gradable polymeric device. Invest Ophthalmol Vis Sci. 1994;35: 2815-2819.
10. Morita Y, Ohtori A, Kimura M, Tojo K. Intravitreous delivery of dexamethasone sodium m-sulfobenzoate from poly(DL-lactic acid) implants. Biol Pharm Bull. 1998;21(2):188-190.
11. Zhou T, Lewis H, Foster RE, Schwendeman SP. Development of a multiple-drug delivery implant for intraocular management of pro-liferative vitreoretinopathy. J Control Rel. 1998;55:281-295.
12. Kunou N, Ogura Y, Yasukawa T, et al. Long-term sustained release of ganciclovir from biodegradable scleral implant for the treatment of cytomegalovirus retinitis. J Control Rel. 2000;68:263-271.
13. Okabe J, Kimura H, Kunou N, Okabe K, Kato A, Ogura Y. Biodegradable intrascleral implant for sustained intraocular delivery of beta-methasone phosphate. Invest Ophthalmol Vis Sci. 2003;44:740-744.
14. Fialho SL, Silva-Cunha A. Manufacturing techniques of biodegradable implants intended to intraocular application. Drug Deliv. 2005;12:109-116.
15. Fialho SL, Rêgo MGB, Siqueira RC, et al. Safety and pharmacokinetics of an intravitreal biodegradable implant of dexamethasone acetate in rabbit eyes. Curr Eye Res. 2006;31:525-534.
16. Tan DTH, Chee S, Lim L, Lim AS. Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of postcata-ract surgery inflammation. Ophthalmology. 1999;106:223-231.
17. Tan DTH, Chee S, Lim L, Theng J, Van Ede M. Randomized clinical trial of Surodex steroid drug delivery system for cataract surgery: anterior versus posterior placement of two Surodex in the eye. Ophthalmology. 2001;108:2172-2181.
18. Siqueira RC, Ribeiro E, Fialho SL, et al. Pharmacokinetic and toxicity investigations of a new intraocular lens with a dexamethasone drug delivery system (IOL-DDS): a pilot study. Ophthalmologica. 2006;220:338-342.
19. Chawla JS, Amiji MM. Biodegradable poly(-caprolactone) nano-particles for tumor-targeted delivery of tamoxifen. Int J Pharm. 2002;249:127-138.
20. Barbato F, La Rotonda MI, Maglio G, Palumbo R, Quaglia F. Biodegradable microspheres of novel segmented poly(ether-ester-amide)s based on poly(-caprolactone) for the delivery of bioactive compounds. Biomaterials. 2001;22:1371-1378.
21. Sinha VR, Bansal K, Kaushik R, Kumria R, Trehan A. Poly- -caprolactone microspheres and nanospheres: an overview. Int J Pharm. 2004;278:1-23.
22. Hiljanen-vainio M, Karjalainen T, Seppala JV. Biodegradable lactone copolymers. 1. Characterization and mechanical behavior of -caprolactone and lactide copolymers. J Appl Polym Sci. 1996;59: 1281-1288.
23. Lemmouchi Y, Schacht E, Lootens C. In vitro release of trypanocidal drugs from biodegradable implants based on poly(-caprolac-tone) and poly(D,L-lactide). J Control Release. 1998;55:79-85.
24. Leroueil-Le Verger M, Fluckiger L, Kim Y-Il, Hoffman M, Maincent P. Preparation and characterization of nanoparticles containing an anti-hypertensive agent. Eur J Pharm Biopharm. 1998;46:137-143
25. Blanco MD, Bernardo MV, Sastre RL, Olmo R, Muñiz E, Teijón JM. Preparation of bupivacaine-loaded poly(-caprolactone) microspheres by spray drying: drug release studies and biocompatibility. Eur J Pharm Biopharm. 2003;55:229-236.
26. Barbault-Foucher S, Gref R, Russo P, Guechot J, Bochot A. Design of poly- -caprolactone nanospheres coated with bioadhesive hyaluronic acid for ocular delivery. J Control Release. 2002;83:365-375.
27. Sun H, Mei L, Song C, Cui X, Wang P. The in vivo degradation, absorption and excretion of PCL-based implant. Biomaterials. 2006;27:1735-1740.
28. Beeley NR, Rossi JV, Mello-Filho PA, et al. Fabrication, implantation, elution, and retrieval of a steroid-loaded polycaprolactone subretinal implant. J Biomed Mater Res A. 2005;73(4):437-444.
29. Merkli A, Tabatabay C, Gurny R, Heller J. Biodegradable polymers for the controlled release of ocular drugs. Prog Polym Sci. 1998; 23:563-580.
30. Dash AK, Cudworth GC II. Therapeutic applications of implantable drug delivery systems. J Pharmacol Toxicol Methods. 1998; 40:1-12.
31. Culpepper JA, Lee F. Regulation of IL 3 expression by glucocorticoids in cloned murine T lymphocytes. J Immunol. 1985;135: 3191-3197.
32. Lewis GD, Campbell WB, Johnson AR. Inhibition of prostaglandin synthesis by glucocorticoids in human endothelial cells. Endocri-nology. 1986;119:62-69.
33. Grabstein K, Dower S, Gills S, Urdal D, Larsen A. Expression of interleukin 2, interferon-, and the IL 2 receptor by human peripheral blood lymphocytes. J Immunol. 1986;136:4503-4508.
34. Knudsen PJ, Dinarello CA, Strom TB. Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin 1 in U937 cells. J Immunol. 1987;139:4129-4134.
35. Lee SW, Tsou AP, Chan H, et al. Glucocorticoids selectively inhibit the transcription of the interleukin 1gene and decrease the stability of interleukin 1mRNA. Proc Natl Acad Sci U S A. 1988;85:1204-1208.
36. Friedrich S, Cheng YL, Saville B. Finite element modeling of drug distribution in the vitreous humor of the rabbit eye. Ann Biomed Eng. 1997;25:303-314.
37. Tojo K, Isowaki A. Pharmacokinetic model for in vivo/in vitro correlation of intravitreal drug delivery. Adv Drug Deliv Rev. 2001;52:17-24.
38. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthal-mol. 2007;125(3):309-317.
39. National Institutes of Health. ClinicalTrials.gov. Reconstruction of the orbit with a bioresorbable polycaprolactone implant. Available at: http://clinicaltrials.gov/ct2/show?term=polycaprolactone&rank=2. Accessed August 2008.